Abstract: Cosmetic or dermatological preparations with a content of an aqueous extract of Radix Glycyrrhizae inflatae or licochalcone A, one or more ethoxylated or propoxylated raw materials, optionally one or more polyols.

Abstract: Disclosed herein are compositions and methods of using such compositions to modulate pigmentation and proliferation of a melanocyte, such as to prevent or treat skin disorders, including skin cancer or for use for cosmetic purposes. In one example, a method of modulating pigmentation of a melanocyte includes contacting the melanocyte (such as a human melanocyte) with an agent that modulates neuregulin-1 (NRG-1) activity, such as an agent that increases or decreases NRG-1 activity, thereby modulating pigmentation of the melanocyte. In one particular example, the method of increasing melanocyte pigmentation or proliferation can be used to reduce UV skin damage, including that associated with skin cancer. In another example, the method of decreasing melanocyte pigmentation can be used to treat a skin pigmentation disorder associated with undesired increased skin pigmentation.

Abstract: Cosmetic or dermatological preparations having an effective content of one or more thiazoles of the general formula

Abstract: A topical cosmetic and dermatological preparation for reducing skin reddening which comprises (1R,2S,5R)-2-isopropyl-5-methyl-N-(2-(pyridin-2-yl)ethyl)-cyclohexane carboxamide and/or (1R,2S,5R)—N-(4-cyanomethyl-phenyl)-2-isopropyl-5-methylcyclohexane carboxamide.

Abstract: Transdermal therapeutic systems that contain 4-n-butylresorcinol as an active ingredient.

Abstract: Use of topical, cosmetic or dermatological preparations with a content of (1R,2S,5R)-2-isopropyl-5-methyl-N-(2-(pyridin-2-yl)ethylcyclohexanecarboxamide and/or (1R,2S,5R)-N-(4-(cyanomethyl)-phenyl)-2-isopropyl-5-methylcyclohexyl carboxamide for reducing itching.

Abstract: Post-foaming cosmetic cleansing preparation on an aqueous basis which is suitable for dispensing from an aerosol container, containing in a conventional aqueous base preparation a) detersive surfactants with saturated radicals, preferably anionic surfactants and non-ionic surfactants and/or amphoteric surfactants, b) 2.5 to 25% by volume, preferably 5 to 20% by volume, particularly preferably 7.5 to 15% by volume of pure oxygen.

Abstract: The present invention relates to the use of licochalcone A for the treatment of rosacea.

Abstract: A cosmetic or pharmaceutical preparation comprising licochalcone A and one or more hydrocolloids. This Abstract is not intended to define the invention disclosed in the specification, nor intended to limit the scope of the invention in any way.

Abstract: A topical cosmetic and dermatological preparation for reducing skin reddening which comprises (1R,2S,5R)-2-isopropyl-5-methyl-N-(2-(pyridin-2-yl)ethyl)-cyclohexane carboxamide and/or (1R,2S,5R)—N-(4-cyanomethyl-phenyl)-2-isopropyl-5-methylcyclohexane carboxamide.

Abstract: A cooling topical cosmetic or dermatological preparation which comprises (1R,2S,5R)-2-isopropyl-5-methyl-N-(2-(pyridin-2-yl)ethyl)cyclohexane carboxamide and/or (1R,2S,5R)-N-(4-cyanomethyl-phenyl)-2-isopropyl-5-methylcyclohexane carboxamide, in combination with menthoxypropanediol.

Abstract: Post-foaming cosmetic cleansing preparation on an aqueous basis which is suitable for dispensing from an aerosol container, containing in a conventional aqueous base preparation a) detersive surfactants with saturated radicals, preferably anionic surfactants and non-ionic surfactants and/or amphoteric surfactants, b) 2.5 to 25% by volume, preferably 5 to 20% by volume, particularly preferably 7.5 to 15% by volume of pure oxygen.

Abstract: The invention relates to oligoribonucleotides, which are capable of inducing breakdown of the mrna enzymes that break down connective tissue, and to pharmaceutical and cosmetic compositions, which are provided for topical application and which contain the oligoribonucleotides. The compositions are particularly suited for treating degenerative skin disorders.

Abstract: A cosmetic preparation comprising one or more compounds selected from salicylic acid and salts thereof and glycolic acid and salts thereof and one or more pigments selected from titanium dioxide pigments and zinc oxide pigments. This Abstract is not intended to define the invention disclosed in the specification, nor intended to limit the scope of the invention in any way.

Abstract: Use of licochalcone A or of an extract containing licochalcone A from Radix Glycyrrhizae inflatae in cosmetic and dermatological preparations for the treatment and prophylaxis of the symptoms of intrinsic and/or extrinsic skin ageing and the treatment and prophylaxis of the damaging effects of ultraviolet radiation on the skin.

Abstract: The present invention relates to the use of licochalcone A for the treatment of rosacea.

Abstract: Active ingredient combinations of (a) one or more 2,3-dibenzylbutyrolactone derivatives and (b) licochalcone A or an aqueous extract of Radix Glycyrrhizae inflatae containing licochalcone A.

Abstract: Use of molecular oxygen in cosmetic or dermatological preparations for the prophylaxis and treatment of a flawed appearance of the skin and/or of the cutaneous appendages as can arise through extrinsic and intrinsic and/or age-related or UV-induced disturbances.

Abstract: Cosmetic and/or dermatological preparation containing one or more 2,3-dibenzylbutyrolactone derivatives and/or their glycosides besides optionally additional cosmetic and/or dermatological active ingredients, auxiliary agents, and additives.

Abstract: The invention relates to oligoribonucleotides, which are capable of inducing breakdown of the mRNA enzymes that break down connective tissue, and to pharmaceutical and cosmetic compositions, which are provided for topical application and which contain the oligoribonucleotides. The compositions are particularly suited for treating degenerative skin disorders.